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Summary 
Ovalbumin (OVA)-specific CD8 + T  cells from the T  cell receptor-transgenic line OT-I (OT-I 
cells) were injected into unirradiated transgenic 1KIP-mOVA mice, which express a membrane- 
bound  form of OVA  (mOVA) in the  pancreatic islet  [3  cells  and the  renal proximal tubular 
cells.  OT-I cells  accumulated in the draining lymph nodes  (LN)  of the kidneys and pancreas 
and in no other LN. They displayed an activated phenotype and a proportion entered cell cy- 
cle. Unilateral nephrectomy 7-13 d before inoculation of OT-I ceils into 1KIP-mOVA mice al- 
lowed the injected T  cells to home only to the regional LN of the remaining kidney (and pan- 
creas), but when the operation was performed 4 h before injecting the T  ceils,  homing to the 
LN of the excised kidney was evident. When the bone marrow of RIP-mOVA mice was re- 
placed with one of a major histocompatibility haplotype incapable of presenting OVA to OT-I 
cells,  no homing or activation was detectable. Therefore, OT-I cells were activated by OVA 
presented by short-lived antigen-presenting cells of bone marrow origin present in the draining 
LN of OVA-expressing tissue.  These  results provide the  first  evidence  that  tissue-associated 
"self" antigens can be presented in the context of class I via an exogenous processing pathway. 
This offers a constitutive mechanism whereby T  cells can be primed to antigens that are present 
in nonlymphoid tissues,  which are not normally surveyed by recirculating naive T  cells. 
A 
ntigens  presented  in  association with MHC-encoded 
class I molecules are generally derived from intracellu- 
larly synthesized proteins  (1).  In contrast,  exogenous anti- 
gens are taken up by APC and presented with MHC class 
II molecules. Under some circumstances, however, exoge- 
nous antigens have been reported to enter the  class I pre- 
sentation pathway in vivo. This was first suggested by cross- 
priming experiments, where MHC-mismatched grafts could 
prime recipients for a  cytotoxic CD8 +  T  lymphocyte re- 
sponse specific for minor histocompatibility antigen  (HA) 1 
(2),  H-Y antigen (3), or SV-40 antigen (4). Presentation of 
the donor minor antigens in the context of host class I mol- 
ecules required  antigen processing and presentation by re- 
cipient APC, violating the separation between the two an- 
tigen-processing  pathways.  Such  cross-priming  was  later 
shown for the induction of CTL to the more conventional 
antigens OVA and ~-gal, where mice were primed by the 
intravenous  injection  of antigen-coated  spleen  cells  (5). 
~  Abbreviations used in this  paper: B6, C57BL/6; BrdU, bromodeoxyuridine; 
HA, histocompatibility  antigen; HSP, heat shock protein; mOVA, mem- 
brane-bound form of OVA; OT-l, OVA-specific,  class l-restricted T cells. 
Furthermore,  certain nonself antigens,  such as tumor anti- 
gens  (6)  or  antigens  carried  by microorganisms  (7),  have 
been reported to access the  class I pathway. Tolerance  to 
donor minor HA in nude mice that received thymus grafts 
expressing both minor and major HA incompatibility sug- 
gested that this pathway operates in the thymus (8). 
Attempts  to  identify  an  exogenous  class  I  presentation 
pathway in vitro remain contradictory. In these studies, sol- 
uble antigens (9,  10) or antigens carried by microorganisms 
(11) or beads (12,  13) have been incubated with various APC 
that were then shown to present antigen to class I-restricted 
T  cell hybridomas. Some reports have attributed such pre- 
sentation to specialized APC that shunt exogenous antigens 
into  the  class  I  pathway  (13-15).  The  relevance  of these 
findings has been questioned, however, by the observation 
that particle  overloading of the  phagosomal compartment 
may cause mechanical disruption resulting in antigen escap- 
ing into the cytosol (16). 
Collectively, recent work on the exogenous presentation 
of class I-restricted antigens  has focused on the  introduc- 
tion of nonself antigens into this pathway, The report pre- 
sented here provides evidence that self antigens  expressed 
by healthy tissues  can be processed by a constitutively act- 
ing exogenous pathway for class I presentation.  This may 
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infection or malignancy. 
Materials  and Methods 
Mice.  All mice were bred and maintained at the Walter and 
Eliza Hall Institute for Medical Research. Female mice between 8 
and 16 wk old were used. 
RIP-mOVAMice.  The  membrane-bound  form  of  OVA 
(mOVA) consists of a fusion protein made up of the first  118 res- 
idues of the human transferrin receptor, which includes the cyto- 
plasmic tail and signal/anchor domain and is  linked to  residues 
139-385  from mature  OVA.  The  cDNA  encoding the  mOVA 
fusion protein was excised from the pSVT7-OVA/TfR plasmid 
(17) by digestion with HindlII after converting the BgllI site situ- 
ated 3'  to  the  coding region to  a Hindlll site using a synthetic 
linker (Promega, Madison, WI). This cDNA fragment was then 
cloned into the unique HindlII site of the pBlueRIP vector (18), 
which  brings it  under the  control  of the  rat  insulin promoter 
(RIP).  Vector  sequences were  excised by digestion with ApaI, 
Notl and PvuI. The  purified DNA was  microinjected into the 
pronuclei of C57BL/6 fertilized eggs as described (19). 
&reening for the Presence of the  OVA  Transgene in RIP-mOVA 
Mice.  DNA from blood of RIP-mOVA mice was prepared us- 
ing Instagene-Matrix (BioRad Laboratories, Hercules, CA). DNA 
encoding OVA was amplified by PCR using the primers 5' CAA- 
GCACATCGCAACCA and 3' GCAATTGCCTTGTCAGCAT, 
which  cover  a  480-bp  fragment.  As  positive  controls,  primers 
specific for  mouse insulin were  used.  PCR  reagents were  pur- 
chased from Promega. After 35 cycles (60 s 95~  60 s 55~  60 s 
72~  amplified DNA was detected on a  1.2% agarose gel con- 
taining ethidiumbromide. 
Preparation of OVA-spec!fic, class I-restricted T  Cells (OT-I)  Cells 
for Adoptive Transfer.  OT-I mice producing OVA-specific CD8 + 
T  cells (20)  were crossed to a RAG-l-/-  background to prevent 
endogenous rearrangement of TCRs and to avoid generation of 
CD4 + T  cells  and B  cells.  To remove erythrocytes and macro- 
phages,  the  LN and spleen cells  of OT-I mice  were  first  incu- 
bated with anti-HSA (Jl ld [2l]) culture supernatant, followed by 
treatment with rabbit complement. Debris was removed by filter- 
ing the cell suspension through a 100-txm mesh. 5-10 ￿  10  ~ cells 
were injected intravenously into unirradiated recipient mice. 
FACS  ~ Analysis.  For three-color FACS  |  (Becton Dickinson 
&  Co.,  Mountain View,  CA)  analysis,  cells  from  single LN  or 
spleen were  stained as described before  (22)  using the following 
mAbs:  PE-conjugated  anti-CD8  (YTS  169.4)  was  purchased 
fiom Caltag Laboratories,  San Francisco, CA. Biotinylated anti- 
CD69 (H1 .SF3) and FITC- and biotin-labeled anti-Thyl.l (OX-7) 
were  from  PharMingen  (San  Diego,  CA).  Anti-V0~2  TCR 
(1320.1  [23]),  anti-V135.1/2  TCR  (MR9-4  [24],  anti-CD44 
(IM7.81  [25]), and anti-c-selectin (Mel-14 [26]) mAbs were con- 
jugated  to  biotin or  to  FITC using standard protocols.  Biotin- 
labeled  Abs  were  detected  with  streptavidin  (SAVP)-Tricolor 
(Caltag). Analysis was performed on a FACScan  |  (Becton Dick- 
inson) using Lysis II software. Live gates were set on lymphocytes 
by forward and side scatter profiles. 10,000-20,000 live cells were 
collected  for analysis. To  identify OT-1 donor cells  in  the  LN 
from recipient mice, two staining protocols were used: First, OT-I 
cells were identified by staining for Voe2  + V135  + CD8 + cells, and 
the proportion ofVoe2 + V135  + CD8 + cells in all CD8 + cells was 
used as an indicator of homing. This proportion in a noninjected 
RIP-mOVA mouse was  1.4%.  Proportions of C1)8 + cells above 
this background were considered to be OT-I cells. Second, RIP- 
mOVA mice were  crossed  to  B6kathy  mice,  thereby acquiring 
the Thyl. 1 molecule on T cells. Transferred OT-I cells were 11o- 
mozygous  for  Thyl.2.  Therefore,  staining for  Thyl.l  Vow2  ~ 
CD8 + cells identified OT-I cells of donor origin. To evaluate ex- 
pression  of surface  activation  markers,  cells  were  stained  with 
Thyl.I-FITC, CD8-PE, and biotinylated Abs specific for C1)44, 
CD69, and L-selectin. 
Analysis for Bromodeoxyuridine (BrdU) h,lcorporation of Tramferred 
O%lCells.  Recipient mice  were  injected with  1.5  mg BrdU 
(Sigma lmmunochemicals, St.  Louis, MO)  in two doses 24  and 
12  h  before  analysis.  Lymphocytes prepared  from  LN  of these 
mice were stained with CDS-PE and biotinylated anti-Thyl.l or 
anti-Vow2, followed by SAVP-Tricolor,  as  described above.  In- 
corporated  BrdU  was  detected  as  described  previously  (27). 
Briefly,  stained cells  were  fixed  for  30  rain with  70%  ice-cold 
ethanol, and then with 0.5% paraformaldehyde +  0.05% Tween 
20 for 30 rain at room temperature. Then they were treated with 
50 Kunitz U/0.5 ml DNAse I  (Sigma)  for 10 rain at room tem- 
perature, followed by incubation with an FITC-conjugated anti- 
BrdU Ab (Becton Dickinson). 
MLR.  LN cells from RIP-mOVA or nontransgenic mice in- 
jected with OT-I cells were used as responders. The number of 
OT-I  cells  was  detemfined  by  FACS  |  analysis,  as  described 
above. As stimulators, OVA-peptide pulsed or not pulsed synge- 
neic 1,500 cGy irradiated spleen cells were used. Cells were cul- 
tured  in  96-well  plates  using RPMI-1640  supplemented  with 
10% FCS and 50 ~*M 2-ME for 1 or 2 d. After pulsing the wells 
with  1  ~Ci  [3H]thymidine for  8  b,  cells  were  harvested  onto 
glassfiber filters for scintillation counting. The OVA-peptide SIIN- 
FEKL was  synthesized using a  synthesizer (model  431;  Applied 
Biosystems, Inc., Foster City,  CA),  and was provided by Dr. J. 
Fecondo (Swinburne University of Technology,  Hawthorn, Vic- 
toria, Australia). 
Immunohistolqw for OVA Expression.  hnmunostaining  was car- 
ried out as described (19).  Briefly, frozen tissue sections were in- 
cubated  with  rabbit anti-OVA antiserum that  was  obtained by 
immunizing rabbits with whole OVA (grade V; Sigma). After in- 
cubation with  swine anti-rabbit Ig-HRPO  (DAKO,  Glostrup, 
Denmark),  HRPO  was  developed  with  DAB  (Sigma).  Slides 
were counterstained with hematoxylin. 
Nephrectomy.  The peritoneal cavity of anaesthetized mice was 
opened by a lateral cut. The kidney was carefully lifted, and the 
hilus vessels were ligated. The kidney was then removed, leaving 
kidney LN, adrenal gland, and vena testicularis in situ. 
Bone Marrow Chimeras.  Bone  marrow  replacement  was  car- 
ried out as described (22).  Recipient mice were lethally irradiated 
with 900 cGy at 7-8 wk of age, and were  reconstituted on the 
same day with  0.5-1.0  X  107 bone nrarrow cells  that were  de- 
pleted of mature T  cells. 
Results 
Expression of OVA  in RIP-mOVA  Mice.  Immunohisto- 
logical examination revealed OVA expression in pancreatic 
[3 cells and kidney proximal tubular cells (Fig.  1), but not in 
the  liver, intestine,  stomach,  spleen,  LN,  thymus,  salivary 
glands,  adrenal  gland,  lung,  heart,  connective  tissue,  and 
ovaries  (data not shown).  Low level expression was  found 
in the  testes  (data not shown).  The  experiments presented 
in  this  paper  use  only  female  tKIP-mOVA  mice.  When 
1KIP-mOVA mice were crossed to OT-I  mice, which pro- 
duce OVA-specific CD8 +  T  cells, double transgenic mice 
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Figure 2,  Homing of OT-1 cells to the draining lymph nodes of OVA 
expressing tissues in P,  IP-mOVA mice. 3 d after intravenous injection of 
7.5 ￿  10  ~' OT-I cells into P,  IP-mOVA mice and nontransgenic littermate 
mice,  OVA-specific  CD8  cells were  detected  by  lzACS  |  analysis for 
CD8 +, V~x2  +, and V[35  + cells. The horizontal line at 1.4% represents the 
proportion of Vc~2  + and V[35  + cells among the CD8 + cells in nonin- 
jected RIP-mOVA nfice. The LN draining particular organs such as the 
kidney or the  pancreas had been mapped by injecting Fount India ink 
(Pelikan, Hannover, Germany) into the organ of interest and identifying 
24 h later those LN that had accunmlated ink particles. Experiments were 
performed  at least four times. P,  epresentative results are given here.  I 
RIP-mOVA mice; [], nontransgenic littermates 
Figure  1.  Expression  of OVA  in  P,  IP-mOVA  mice.  Immunohis- 
tochemistry performed on kidney (A) and pancreas (B) sections. The ar- 
row in A indicates a proximal tubule originating from a glomerulus. 
showed  thymic  deletion  of OT-I  cells  (data  not  shown). 
This suggested that mOVA  was present in low amounts at 
this site. 
Homing of OT-I Cells to the Draining LN of OVA-express- 
ing Tissues in RIP-mOVA Mice.  To  examine  the  fate  of 
OVA-specific  CD8 +  T  cells  after  antigen  encounter  in 
vivo, these  cells were  injected intravenously into unirradi- 
ated adult female R.IP-mOVA mice. After 3  d, the LN and 
spleen of the recipient mice were analyzed for the presence 
of OT-I  cells (Fig. 2). In the draining LN of OVA-express- 
ing tissues,  namely the kidneys and the pancreas,  the pro- 
portion  of OT-I  CD8 +  cells  among the  total  CD8 +  cells 
was two- to sixfold higher in the kidney and pancreatic LN 
than in the pyloric, mesenteric, inguinal, or cervical LN, or 
in the spleen. No such accumulation or "homing" was de- 
tected  in  nontransgenic littermate  controls.  The  total  cell 
number in the  two  renal LN  was  not statistically different 
in P-,IP-mOVA and nontransgenic littermate  mice  (1.8  + 
0.5  ￿  10  e' cells vs.  1.5  +  0.3  ￿  106  cells, mean of 15 hom- 
ing experiments). No homing was detected in axillary, bra- 
chial, gastric, or popliteal LN  (data not shown). 
To assess the kinetics of homing, draining LN were ana- 
lyzed 22, 30, 42, 68, and 160 h  after T  cell transfer (Fig. 3). 
Homing was maximal after 3  d  and had decreased by day 7. 
A  slight increase in OT-I  cells was also detected in control 
LN  between  22 and  30  h,  but  this  is  likely to  reflect  in- 
jected  OT-I  cells joining the  pool  of recirculating CD8 + 
cells. 
Homing 0%I Cells Are Activated In  Vivo.  To determine 
whether  OT-I  cells were  activated upon homing, the sur- 
face  activation markers  CD44,  CD69,  or  L-selectin were 
examined.  Three  control  cell  populations  were  used:  (a) 
non-OVA-specific  CD8 +  cells  present  in  the  same  LN 
(CD8 + Vcl2- cells); (b) OT-I  cells prepared from a LN that 
Figure  3. 
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nontransgenic  littermate  mice were  analyzed at various timepoints after 
injection of 7.5  ￿  10  ~' OT-I cells, and the proportion of OT-I cells per 
CD8 + cells was determined.  ~-, Renal LN, RIP-mOVA; ~-, inguinal 
LN, R.IP-mOVA; -O-, renal LN, nontransgenic littermate. 
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Figure  4.  Expression  of acti- 
vation markers by homing OT-I 
cells.  3  d  after injection  of 5  ￿ 
10  r' OT-I cells into RIP-mOVA 
mice, the expression of the acti- 
vation  markers  CD44,  CD69, 
and  L-selectin  was  investigated 
on CD8 + Vot2 + cells in the renal 
LN  (upper  row),  CD8 +  Vow2 
cells in the same LN (second row), 
on CD8 +  V~2 +  cells  in  the in- 
guinal  LN  (third  row) of  RIP- 
mOVA  mice,  and  on  CI)8 ~ 
V(x2 + cells From the renal LN of 
nontransgenic  littermate  mice 
(bottom row). Expression of C1)69 
was determined in a separate ex- 
periment.  All  profiles  are  repre- 
sentative for several such experi- 
nlents. 
does  not  drain  OVA-expressing  tissues  in  ILIP-mOVA 
mice,  such as the inguinal LN;  (c)  OT-I  cells prepared  from 
the renal LN  of a  nontransgenic  littermate  mouse. 
In  contrast  to  control  populations,  OT-I  cells  that 
homed  to  the renal LN  of the P, IP-mOVA  mouse  upregu- 
lated CD44  and CD69  and downregulated  L-selectin  (Fig.  4). 
To  determine  whether  activation led to  the proliferation  of 
OT-I  ceils, the recipient mice were injected with BrdU  24 h 
Figure  5.  Proliferation  of  homing 
OT-I cells. 3 d after injection oF5  ￿  ll)  ~' 
OT-I  cells  into  R.IP-mOVA mice,  the 
presence of BrdU was detected in (;1)8 § 
Thyl.1  cells  in the renal and the pan- 
creatic  LN.  Similar controls were  given 
as  in  Fig.  3.  Recipient  mice  had  been 
injected with 1.5 mg BrdU in two doses 
24 and 12 h before analysis. 
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Figure  6.  Restimulation  of  OT-I 
cells  in  vitro.  RIP-mOVA  and  non- 
transgenic littermate mice were injected 
intravenous with  6  ￿  106  OT-I  cells. 
After 3 d, cells from the renal (  ) or 
the inguinal (  ....  ) LN of RIP-mOVA 
recipients  or from the renal lymph node 
of a  nontransgenic  recipient  (  ....  ) 
were  cocultured  in  different  dilutions 
with 5 ￿  10  ~ irradiated  syngeneic spleen 
cells pulsed or not pulsed with the OVA 
peptide.  The  proportion of OT-I  cells 
in  LN cells was determined by FACS  | 
analysis. 18 and 42 h after restimulation, 
incorporation of [3H]thymidine over 8 h 
was determined￿9 Mixed lymphocyte re- 
actions  were done in duplicate  and the 
response  to  nonpulsed  stimulators  was 
subtracted.  This response to  nonpulsed 
stimulators was 529  cpm on  day  1 and 
798 cpm on day 2 for the highest number ofresponder cells from the renal LN of RIP-mOVA mice.  Comparable background responses were found for 
stimulators from control LN. Error bars indicate  standard  errors. The results are representative of two such experiments. 
before analysis  (Fig.  5).  At least 50% of OT-I cells  (V~x2  + 
CD8 + cells) in the kidney and pancreatic LN had incorpo- 
rated BrdU, whereas little incorporation was seen for non- 
antigen-specific cells  or OT-I cells present in LN that did 
not  drain  OVA-expressing  tissues.  When  homing  OT-I 
cells from the renal LN of RIP-mOVA mice were restimu- 
lated  in  vitro  with  antigen,  they  showed  antigen-specific 
proliferation within  l  d,  whereas OT-I cells  from control 
LN responded to antigen later (Fig.  6). 
CD4 + help was not required for OT-I cell activation in 
our model because homing and CD69 expression were not 
abolished by depleting CD4 + cells  in P, IP-mOVA recipi- 
ents, and CD4 + cells in RIP-mOVA mice were specifically 
tolerant of OVA (data not shown). 
The BrdU incorporation by OT-I ceils in the renal LN 
at  day  3  indicated  that  their  accumulation  was  not  only 
caused by strict homing, but also by proliferation. For sim- 
plicity, however,  OT-I cells  that have accumulated in the 
renal LN of RIP-mOVA mice will be referred to as hom- 
ing OT-I cells. 
OT-I  Cells  Proliferate  in  the  Renal  LN  after  Nephrectomy. 
If OT-I cells were activated after encountering antigen on 
kidney tubular cells,  neither homing nor signs of activation 
should be detected in the renal LN draining the site of an 
excised  kidney.  Therefore,  left  nephrectomy  was  per- 
formed before the injection of OT-I cells, leaving the right 
kidney and the draining LN of the left kidney in situ.  3  d 
after OT-I cell transfer, homing to the left and right renal 
LN were compared. When nephrectomy was performed 4 h 
before transfer, homing of OT-I cells  to the left renal LN 
was comparable to homing to the right renal node. When 
the recipient mice were nephrectomized 7,  10,  or 13 d be- 
fore,  however,  no  homing  to  the  left renal  LN was  de- 
tected,  whereas  OT-I cells still  homed to  the  right  renal 
node (Fig.  7) and to the pancreatic node (data not shown)￿9 
A similar result was obtained after removal of the right kid- 
ney (data not shown). No homing was detected in nephrec- 
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tomized littermate  mice.  These  findings  demonstrate  that 
antigen  is  derived  specifically from  the  kidney,  and  they 
rule out nonspecific accumulation of OT-I cells in the LN 
that drain the operation site. 
When  transgenic  CD8 + T  cells  specific for an  antigen 
other than OVA,  such  as H-Y--specific T  cells  (28),  were 
injected  into  nephrectomized  female  RIP-mOVA  mice, 
no selective homing was detected (data not shown). 
OT-I cells that had homed to the left renal LN of RIP- 
mOVA mice nephrectomized 4 h before T  cell transfer had 
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Figure  7.  Homing of OT-I cells after  nephrectomy. 4 h  or 10 d after 
removal of the  left  kidney,  5  ￿  1if'  OT-I cells were injected  intrave- 
nously into RIP-mOVA mice or nontransgenic littermates.  3 d after  in- 
jection,  homing OT-I cells were identified  by staining for CD8 + Vow2  + 
Thy1.1- cells, and the proportion of these cells in all CD8 + cells found in 
the  LN  was calculated.  Each  group consisted  of two mice.  The results 
shown here are representative of  five such experiments. [], Left renal LN; 
I  right renal  LN, [] inguinal LN. ,,~  60-  -~ 
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Figure 8.  Proliferation of homing OT-I cells after nephrectomy. 4 h or 
10 d after removal of the left kidney, 5 ￿  10  r OT-I cells  were injected in- 
travenously into RIP-mOVA mice and nontransgenic littermate mice. 3 d 
after injection, the presence of BrdU was detected in CD8 + Thy1.1- cells 
in the renal and the inguinal lymph nodes. Recipient mice had been in- 
jected with  1.5 nag BrdU in two doses 24 and 12 h before analysis. ~, 
Left renal LN; I, right renal LN, [~, inguinal LN. 
a phenotype similar to that displayed by OT-I cells in non- 
nephrectomized RIP-mOVA  mice. They expressed surface 
activation markers  (data not shown),  and a proportion in- 
corporated BrdU (Fig. 8). 
Homing of OT-I Cells Depends  on  a Bone  Marrou*-derived 
Ceil.  The  above  results  indicated  that  antigen  was  pre- 
sented  to  OT-I  cells in  the  renal  LN,  rather  than  in  the 
kidney itself. To  determine the  origin of the APC  and  to 
formally rule out the migration of tubular cells or MHC- 
peptide complexes, we lethally irradiated RIP-mOVA  mice 
and reconstituted them twice with bone marrow either of 
the H-2  b haplotypes, whose APC can present OVA to OT-I 
cells, or of a mutant haplotype, such as H-2 b''~ or H-2 bI'~, 
whose  APC  have  H-2K  molecules  that  are  unable  to 
present the  OVA-peptide SIINFEKL to OT-I  cells. 8  mo 
after the first bone marrow transfer (and 4 mo after the sec- 
ond),  OT-I  cells  were  injected  into  the  chimeras,  and 
honfing was examined 3 d later (Fig. 9). 
Whereas homing still occurred in RIP-mOVA  mice that 
had  received bone  marrow  from  an  H-2  b mouse  or from 
another  1LIP-mOVA  mouse,  no  homing  was  detected 
when  the  bone  marrow  compartment  was  replaced with 
either bml or bm8. Activation markers were increased only 
on OT-I cells prepared from the renal LN of mice that had 
received bone marrow from  H-2  b mice  (data not shown). 
These data also demonstrate that if there is aberrant expres- 
sion ofmOVA  molecules in bone marrow-derived APC, it 
does not account for the homing phenomenon. 
Discussion 
Presentation of exogenous antigens by MHC  class I mol- 
ecules has been demonstrated in several in vitro studies (9- 
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Figure 9.  Homing of OT-I cells depends on a bone marrow-derived 
cell. I<IP-mOVA mice and nontransgenic littermate control mice were 
reconstituted with bone marrow of either a RIP-mOVA B6, a nontrans- 
genic I36, a nontransgenic bin/, or a nontransgenic bin8 donor 8 and 4 mo 
before analysis￿9  3 d after injection of 6 ￿  10  r  OT-I cells, the proportion 
of CD8 +, Vct2  +, and VI35  + cells in the CD8 + population was deter- 
nfined, ml, Left renal LN; [], inguinal LN. 
11,  13,  15, 29, 30). However, doubt has been cast recently 
on  whether  this  form  of processing  or  cross-presentation 
represents  some  truly  novel  exogenous  pathway,  and  its 
relevance  to  general immune  surveillance has  been  ques- 
tioned.  In particular, as shown  by Reis  e  Sousa and  Ger- 
main  (16),  in  vitro  class  I  processing and  presentation  of 
certain particulate forms  of exogenous  antigens can  result 
from their escape into the cytosol as a consequence of dis- 
ruption  of  phagosomal  membrane  integrity.  While  this 
might be important for class I-restricted T  cell priming by 
certain  intracellular pathogens  replicating within  endoso- 
mal compartments, it may prove too inefficient for the pre- 
sentation of the wider class of exogenous antigens. 
In contrast to the demonstration of cross-presentation in 
vitro, cross-printing (2-5),  and  cross-tolerance (8)  experi- 
ments provide in vivo evidence for access to the exogenous 
class I presentation pathway.  In the early studies of Bevan 
(2),  immunization  with  antigens  expressed  on  aUogeneic 
cells allowed efficient generation of minor histocompatibil- 
ity antigen--specific CTL  that were  restricted to the host's 
class I MHC.  Host APCs must therefore have been able to 
shunt what was essentially exogenous antigen into the class 
I  processing and  presentation pathway for effective T  cell 
activation. 
Previous studies showing in vivo presentation of exoge- 
nous class I-restricted antigens have all involved the delib- 
erate introduction of some foreign agent into  the host  (1, 
31-33).  By contrast,  the  experiments described in this re- 
port show  that  the  antigen involved in  cross-presentation 
in vivo can be  derived from  constitutively expressed pro- 
teins. The  specific homing of the OT-I  cells in  the trans- 
genic  mice  expressing mOVA  in  the  islet [3  cells and  the 
kidney proximal tubules provided a  means of assessing or- 
gan-specific  T  cell  recognition  of peripheral  antigen  in 
vivo.  The  OT-I  cells homed  exclusively to  LN  draining 
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phenotype. This homing and activation was clearly evident 
even after nephrectomy, as long as OT-I cells were injected 
shortly  after  surgery.  Consequently,  the  class I-restricted 
T  cells  recognized  antigen  that  was  presented  within  the 
draining LN and not in the kidney itself. 
Until  now,  the APC  responsible for in vivo cross-pre- 
sentation  has remained  elusive.  The problem with  earlier 
studies  was  the  lack  of knowledge  of the  site  of antigen 
presentation.  The advantage of our RIP-mOVA model is 
that this  site is well defined,  and experiments designed to 
identify the APC can proceed with the knowledge that this 
cell  is  found  within  the  LN that  are  targeted  by homing 
OT-I cells. The APC involved are of bone marrow origin, 
since reconstitution with bm mutant bone marrow, but not 
with C57BL/6,  abrogated OT-I cell homing, further rein- 
forcing  the  notion  that  antigen  recognition  is  not  taking 
place within the kidney itself. 
As yet, it is not known how and where the antigen is in- 
troduced into the APC, but we can envisage several possi- 
bilities, mOVA might have been shed from tubular cells to 
be taken up and processed by APC that are present in the 
kidney  or in  the  draining  LN.  Another  possibility is  that 
heat  shock proteins  (HSP)  carrying mOVA-derived pep- 
tides  might  have  been  released  from  tubular  cells  to  be 
picked  up  by  APC.  Recent  studies  have  suggested  that 
HSP might play a role in cross-priming (34).  In particular, 
macrophages in vitro were shown to interact with HSP96 
and present associated peptides in the context of class I (35). 
Furthermore,  HSP96  purified  from  tumors  could  prime 
CTLs  in  mice  of allogeneic  MHC  haplotypes  (31).  The 
HSP  pathway  may,  however,  constitute  an  inducible 
mechanism that is important when active intervention oc- 
curs, such as during tissue transplantation. 
mOVA  molecules  may follow  an  unusual  presentation 
route, since they contain the transmembrane domain of the 
transferrin receptor. Thus, a signal delivered by this region 
may have been instrumental  in  internalizing  mOVA shed 
from tubular cells into APC. Internalized transferrin recep- 
tors, however, are confined to the lysosomal compartment 
and are thus unlikely to enter the class I pathway (36,  37). 
Alternatively, mOVA molecules may have been degraded 
extracellularly to peptides  that  directly bind  class I  mole- 
cules on APC. This is likely to be a rather inefficient mech- 
anism,  however,  since  the  SIINFEKL peptide  would  be 
only one of many peptides generated by extracellular deg- 
radation of proteins; these peptides would be diluted in the 
extracel/ular fluid,  degraded by serum peptidases, and capable 
of binding only that minor subset  of empty class I  mole- 
cules on the surface of APC. We therefore favor the alter- 
native possibility of some form of direct uptake and pro- 
cessing of antigen by an APC, such as a dendritic cell in the 
kidney, after which this cell migrates to the LN and is there 
involved in T  cell activation. 
Regardless of the method of antigen uptake and process- 
ing in our model, the results we have presented provide the 
first evidence that self antigens expressed by healthy tissues 
can be efficiently processed via an exogenous class I-restricted 
pathway for presentation to CD8 + T  cells.  They also pro- 
vide a plausible answer to a question that has perplexed im- 
munologists for a long time: how can naive CD8 + T  cells 
recognize  foreign  antigens  expressed in  nonlymphoid tis- 
sues through which they do not recirculate (38) and whose 
cells  express few class  I  molecules,  no  class  II molecules, 
and no costimulator molecules? If a pathogen, like a virus, 
has tropism for nonlymphoid tissue cells and cannot infect 
APC, it would be advantageous if the antigen expressed by 
this  tissue  could  proceed  to  the  regional  node,  where  it 
could  stimulate  a  protective  CD8 +  T  cell  response.  Our 
model therefore offers a mechanism by which the antigen 
expressed in infected cells,  and perhaps even in malignant 
cells, could activate naive CD8 + T  cells. 
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